Abstract
Background
Over the past decade, the volume of adverse events (AEs) reported to marketing authorization holders and regulators has been rapidly increasing each year, which has led to significant challenges in patient safety assessment. Three data sources that have largely contributed to the expansion in adverse event reports are patient support programs (PSPs), market research programs (MRPs), and social media. In this study, we sought to further understand the contribution of these safety data sources to the characterization of a product’s safety profile.
Methods
Three separate approaches were taken that, when combined, can be used to evaluate each data source. The first identified any core company data sheet changes or drug safety label changes. The second evaluated the similarity of information through proportions of AEs between each solicited data source and spontaneous sources. Lastly, the completeness of information reported was evaluated through vigiGrade and compared across each data source.
Results
One drug safety label change was identified from a patient support program, which involved regular contact with health care providers. No label changes were identified from market research programs or social media. Patient support programs, market research programs, and social media report similar proportions for HLGT as spontaneous sources. Market research programs and social media display very low vigiGrade scores. When broken down by subtype, traditional PSPs display high vigiGrade scores, while patient assistance programs display lower vigiGrade scores that were program dependent.
Conclusions
This study did not demonstrate that certain data sources such as market research programs, social media, and patient assistance programs meaningfully contributed to the further understanding of the characterization of a product’s safety profile.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Federal Drug Administration. FDA adverse event reporting system public dashboard. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Accessed January 12, 2018.
Federal Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation & Research. Guidance for industry postmarketing adverse experience reporting for human drug and licensed biological products: clarification of what to report. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071981.pdf. Published 1997. Accessed March 15, 2019.
Center for International Organizations of Medical Science. Current challenges in pharmacovigilance: pragmatic approaches: report of CIOMS Working Group V. https://cioms.ch/wp-content/uploads/2017/01/Group5_Pharmacovigilance.pdf. Published 2001. Accessed March 15, 2019.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Post-approval safety data management: definitions and standards for expedited reporting E2D. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf. Published 2003. Accessed March 15, 2019.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VI—Management and reporting of adverse reactions to medicinal products, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129135.pdf Published 2012. Accessed March 15, 2019.
Bergvall T, Noren GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1): 65–77.
Cutts, M. Oxford Guide to Plain English. 4th ed. Oxford: Oxford University Press; 2013.
Robinson, PJ. An Introduction to Information Theory: Symbols, Signals and Noise. Newburyport, MA: Dover Publications, Inc; 1980.
Innovative Medicines Initiative. Innovative Medicines Initiative WEB-RADR Workshop report: mobile technologies and social media as new tools in pharmacovigilance. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/02/WC500221615.pdf. Published 2017. Accessed March 15, 2019.
Harinstein L, Kalra D, Kortepeter CM, Munoz MA, Wu E, Dal Pan GJ. Evaluation of postmarketing reports from industry-sponsored programs in drug safety surveillance. Drug Saf. 2018;42(5):649–655.
Portnoff JM, Lewis DJ. The enigma of pharmacovigilance of patient support programs: a survey of marketing authorization holders in Europe. Therapeutic Innovation & Regulatory Science. 2017;51(4):486–493.
Sharma V.Study on patient support program impact piques EMA’s interest. Pink sheet: pharma intelligence. https://pink.pharmaintelligence.informa.com/PS124066/Study-On-Patient-Support-Program-Impact-Piques-EMAs-Interest. Published 2018. Accessed March 15, 2019.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Press release. https://www.ich.org/fileadmin/Public_Web_Site/News_room/B-Press_Releases/ICH_Press_Releases/ICH38Amsterdam_PressRelease_2019_0614_Final.pdf. Published 2019. Accessed March 15, 2019.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jokinen, J., Bertin, D., Donzanti, B. et al. Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient Safety. Ther Innov Regul Sci 53, 736–745 (2019). https://doi.org/10.1177/2168479019877384
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479019877384